Skip to main content
Shanghai Yizhong Pharmaceutical Co., Ltd. logo

Shanghai Yizhong Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 688091 ISIN · CNE1000050F4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688091

About Shanghai Yizhong Pharmaceutical Co., Ltd.

https://www.yizhongpharma.com

Shanghai Yizhong Pharmaceutical Co., Ltd. is a biopharmaceutical enterprise specializing in the research, development, and commercialization of innovative drug delivery systems. The company focuses on the application of nanotechnology to improve the efficacy and safety of anti-tumor medications. Its core technological platform centers on polymer micelle drug delivery, which enhances the solubility and targeted delivery of hydrophobic drugs. The company's flagship product is Paclitaxel for Injection (Polymeric Micelles), a novel formulation indicated for the treatment of non-small cell lung cancer. This product utilizes a unique block copolymer to encapsulate paclitaxel, aiming to reduce systemic toxicity and eliminate the need for premedication typically required with conventional formulations. Shanghai Yizhong continues to advance its pipeline by applying its proprietary micelle technology to other oncology therapeutics.

Recent filings

Filing Released Lang Actions
上海谊众药业股份有限公司关于在研创新药YXC-001临床试验申请获得受理的自愿性披露公告
Regulatory Filings Classification · 89% confidence The document is a voluntary regulatory disclosure by Shanghai Yizhong Pharmaceuticals concerning the acceptance of an IND clinical trial application for an investigational drug. It contains no financial data or report-style statements; it is an operational/R&D disclosure typical of a regulatory announcement. It does not fit into any financial report category (10-K, IR, ER, etc.) nor specific corporate actions (M&A, dividend, share issue). Therefore, it is classified as a general regulatory filing (RNS).
2026-05-27 Chinese
上海谊众药业股份有限公司关于选举职工董事的公告
Board/Management Information Classification · 93% confidence The document is an announcement by Shanghai Yizhong Pharmaceutical Co., Ltd. regarding the election of an employee director to its Board of Directors. It describes changes in the company’s board composition, which directly falls under the category of Board/Management Information (MANG).
2026-05-27 Chinese
上海谊众_2025年年度股东会资料
AGM Information Classification · 93% confidence The document is titled “2025年年度股东会会议资料” and contains the full set of Annual General Meeting materials—meeting notice, agenda, proposals, attachments (annual report, financial statements, board work report, auditor appointment, director elections, etc.)—which are exactly the materials distributed for an AGM. This matches the definition of AGM Information (AGM-R).
2026-05-27 Chinese
独立董事提名人声明与承诺
Board/Management Information Classification · 75% confidence The document is a formal nomination statement by the board for independent director candidates, detailing their qualifications, commitments, and compliance with governance rules. It is not a financial report, earnings release, proxy solicitation, or regulatory notice but rather pertains to board and director matters. This falls squarely under Board/Management Information (MANG).
2026-05-20 Chinese
上海谊众药业股份有限公司关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a detailed notice of the 2025 annual shareholders’ meeting (AGM) – including date/time/location, agenda items, voting procedures, proxy form and instructions. It is not the meeting presentation or results but is sent to solicit votes and inform shareholders ahead of the AGM. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-20 Chinese
上海谊众药业股份有限公司第二届董事会第十六次会议决议公告
Board/Management Information Classification · 93% confidence The document is a formal announcement of resolutions passed at the company’s board meeting, detailing board election proposals and voting results. It does not contain financial statements, earnings data, or investor presentation materials. This fits the definition of a Board/Management Information announcement regarding board composition changes (MANG).
2026-05-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.